Dr. Ian Smith And Stuart Young Talk About Lessons From Covid-19: Strategy For Recruiting Patients
An Interview with Dr. Ian Smith, Founder, Director and Chief Medical Officer of Panthera Biopartners and CEO of Panthera […]
University of Florida Secures $2.3m for First of its Kind in U.S. Investigating Fatty Liver in Type 2 Diabetics
The University of Florida won a $2.3 million grant in its quest to investigate liver scarring and inflammation triggered by […]
Merck and Hanmi Pharmaceutical Enter into Licensing Agreement to Develop Enopegdutide, an Investigational Once-Weekly Therapy for Nonalcoholic Steatohepatitis (NASH)
Merck,known as MSD outside the United States and Canada, and Hanmi Pharmaceutical today announced that the companies have entered into […]
Penn State Launches Novel Clinical Trial Targeting NASH with Exercise & No Pharmaceuticals
Penn State researchers developed a first-of-its-kind clinical trial to investigate the impact of exercise on a severe form of nonalcoholic […]
Special Edition: Coronavirus Rundown
</p This is a special edition episode to make it easy for you to keep up with our reporting on […]
The World’s First NASH Drug Approved in India: Zydus Cadila’s Saroglitazar
A drug maker in India, Zydus Cadila, has become the first pharma company worldwide to secure a regulatory agency greenlight […]
Dr. Safad from Hadassah Medical Center Produces Promising Results from Namodenoson for Obesity
A clinical trial recently produced data that an experimental drug called Namodenoson, developed in Israel, induces weight loss in experimental […]
Study Evidences Superior Technology to Assess NASH During Clinical Trials
An international team of pathologists and hepatologists from China, Singapore, Europe and America concluded a study successfully testing qFIBS, a […]
Novo Nordisk Enters Race to Develop NASH Treatment
The obesity epidemic has helped usher in a non-alcoholic steatohepatitis crisis. Novo Nordisk, one of the few drugmakers making big […]
KOL Hepatologist to Discuss Clinical Trial Results for Patients with Alcoholic Hepatitis
Tarek I Hassanein, MD, an expert hepatologist and clinical investigator, presents for DURECT Corporation as Key Opinion Leader or “KOL” on the […]
